Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

Summary

Actinium Pharmaceuticals announced three presentations at SNMMI 2026 highlighting ATNM-400's differentiated profile in lung and prostate cancer, including data demonstrating potential in KRAS-mutated NSCLC models as a mutation-agnostic therapy.